![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://www.bmj.com/content/bmj/385/bmj-2023-078483/F2.large.jpg)
dpp4 vs sglt2 vs glp-1
Shipping Estimate
dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]
USD21.98
USD65.98
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/dpp4.png?w=600&tok=f9724b)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://www.researchgate.net/publication/49602453/figure/tbl1/AS:669971042562051@1536744952276/Comparison-of-GLP-1-receptor-agonists-and-DPP-4-inhibitors.png)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=10155413610538341&get_thumbnail=1)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://medizinonline.com/wp-content/uploads/2020/12/tab1_hp10_s14.png)
![dpp4 vs sglt2 vs glp-1 SGLT-2 inhibitors, receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study sitagliptin [TUSOM | Pharmwiki]](https://onlinelibrary.wiley.com/cms/asset/52ae333b-d0e7-4c2e-9c10-5cdb17bee08f/ejhf1673-fig-0001-m.jpg)
